The collaboration will involve Evotec's Panomics platform, which integrates the analysis of genomic, transcriptomic, and proteomic data.
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.
The deal gives Celgene access to ImiDomics' database of genomic markers derived from biological samples for immune-mediated inflammatory diseases.
Most recently, Celgene has licensed the GNS platform for internal use and made an undisclosed equity investment in the company.
The partners aim to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve disease diagnosis, prognosis, and treatment.
Tempus will sequence and analyze pancreatic and melanoma cancer data from Penn patients to identify patterns associated with a positive response to treatment.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.
The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.
ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.
In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.